The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Nakano K, Taira S, Ono M, Tomomatsu J, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, Mitani H, Takahashi S

Incidence and risk factors of interstitial lung disease (ILD) of head and neck cancer patients treated with Cetuximab.

Annals of oncology : official journal of the European Society for Medical Oncology 2017 Oct;28 Suppl 9;ix78 — 2017 Oct — ix78

Nakano K, Seto A, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, Mitani H, Takahashi S

Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab.

Head & neck 2019 Mar 04;; — 2019 Mar 04

Mayfield JD, Mercado CE, Kaye FJ, Mendenhall WM

Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck.

Head & neck 2019 Apr;41;E55-E58 — 2019 Apr — E55-E58

Shablak A, Conn A

A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment.

Targeted oncology 2014 Jun;9;177-80 — 2014 Jun — 177-80

Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010 Nov;5;1855-8 — 2010 Nov — 1855-8

Lai JI, Wang WS, Lai YC, Lin PC, Chang SC

Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy.

International journal of clinical pharmacology and therapeutics 2010 Jul;48;425-8 — 2010 Jul — 425-8